Clinical Performance of the Implantable Cardioverter‐Defibrillator

M. MIROWSKI; PHILIP R. REID; MORTON M. MOWER; LEVI WATKINS; EDWARD V. PLATIA; LAWRENCE S.C. GRIFFITH; THOMAS GUARNIERI; ANDRA THOMAS; JUAN M. JUANTEGUY

doi:10.1111/j.1540-8159.1984.tb05706.x

Clinical Performance of the Implantable Cardioverter‐Defibrillator

M. MIROWSKI, PHILIP R. REID, MORTON M. MOWER, LEVI WATKINS, EDWARD V. PLATIA, LAWRENCE S.C. GRIFFITH, THOMAS GUARNIERI, ANDRA THOMAS, JUAN M. JUANTEGUY

School of Medicine

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

The automatic implantable cardioverter‐defibrillator has been implanted in 276 patients with ventricular tachyarrhythmias refractory to therapy with a follow‐up period up to 50 months (average 9.75 months). The functional performance of the device has so far been most encouraging. The risks and complications associated with its use are acceptable and quite similar to those observed in patients with implanted pacemakers. Acceleration of ventricular tachycardia to a faster rhythm or to ventricular fibrillation is dealt with successfully through recycling. Actuarial analysis indicates that the device has a significant impact on the survival rate of the implantees, reducing the one‐year mortality rate attributed to arrhythmias to only 2%.

Original language	English (US)
Pages (from-to)	1345-1350
Number of pages	6
Journal	Pacing and Clinical Electrophysiology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1111/j.1540-8159.1984.tb05706.x
State	Published - Nov 1984

Keywords

implantable dafibrillator
sudden death
ventricular arrhythmias

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1111/j.1540-8159.1984.tb05706.x

Cite this

@article{453c25cbb818420f903384362a7353fb,

title = "Clinical Performance of the Implantable Cardioverter‐Defibrillator",

abstract = "The automatic implantable cardioverter‐defibrillator has been implanted in 276 patients with ventricular tachyarrhythmias refractory to therapy with a follow‐up period up to 50 months (average 9.75 months). The functional performance of the device has so far been most encouraging. The risks and complications associated with its use are acceptable and quite similar to those observed in patients with implanted pacemakers. Acceleration of ventricular tachycardia to a faster rhythm or to ventricular fibrillation is dealt with successfully through recycling. Actuarial analysis indicates that the device has a significant impact on the survival rate of the implantees, reducing the one‐year mortality rate attributed to arrhythmias to only 2%.",

keywords = "implantable dafibrillator, sudden death, ventricular arrhythmias",

author = "M. MIROWSKI and REID, {PHILIP R.} and MOWER, {MORTON M.} and LEVI WATKINS and PLATIA, {EDWARD V.} and GRIFFITH, {LAWRENCE S.C.} and THOMAS GUARNIERI and ANDRA THOMAS and JUANTEGUY, {JUAN M.}",

year = "1984",

month = nov,

doi = "10.1111/j.1540-8159.1984.tb05706.x",

language = "English (US)",

volume = "7",

pages = "1345--1350",

journal = "Pacing and Clinical Electrophysiology",

issn = "0147-8389",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Clinical Performance of the Implantable Cardioverter‐Defibrillator

AU - MIROWSKI, M.

AU - REID, PHILIP R.

AU - MOWER, MORTON M.

AU - WATKINS, LEVI

AU - PLATIA, EDWARD V.

AU - GRIFFITH, LAWRENCE S.C.

AU - GUARNIERI, THOMAS

AU - THOMAS, ANDRA

AU - JUANTEGUY, JUAN M.

PY - 1984/11

Y1 - 1984/11

N2 - The automatic implantable cardioverter‐defibrillator has been implanted in 276 patients with ventricular tachyarrhythmias refractory to therapy with a follow‐up period up to 50 months (average 9.75 months). The functional performance of the device has so far been most encouraging. The risks and complications associated with its use are acceptable and quite similar to those observed in patients with implanted pacemakers. Acceleration of ventricular tachycardia to a faster rhythm or to ventricular fibrillation is dealt with successfully through recycling. Actuarial analysis indicates that the device has a significant impact on the survival rate of the implantees, reducing the one‐year mortality rate attributed to arrhythmias to only 2%.

AB - The automatic implantable cardioverter‐defibrillator has been implanted in 276 patients with ventricular tachyarrhythmias refractory to therapy with a follow‐up period up to 50 months (average 9.75 months). The functional performance of the device has so far been most encouraging. The risks and complications associated with its use are acceptable and quite similar to those observed in patients with implanted pacemakers. Acceleration of ventricular tachycardia to a faster rhythm or to ventricular fibrillation is dealt with successfully through recycling. Actuarial analysis indicates that the device has a significant impact on the survival rate of the implantees, reducing the one‐year mortality rate attributed to arrhythmias to only 2%.

KW - implantable dafibrillator

KW - sudden death

KW - ventricular arrhythmias

UR - http://www.scopus.com/inward/record.url?scp=0021703510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021703510&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8159.1984.tb05706.x

DO - 10.1111/j.1540-8159.1984.tb05706.x

M3 - Article

C2 - 6209681

AN - SCOPUS:0021703510

SN - 0147-8389

VL - 7

SP - 1345

EP - 1350

JO - Pacing and Clinical Electrophysiology

JF - Pacing and Clinical Electrophysiology

IS - 6

ER -

Clinical Performance of the Implantable Cardioverter‐Defibrillator

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this